新辅助免疫治疗对进展期胃癌术后并发症及短期疗效的影响
回顾性队列研究纳入103例进展期胃癌患者,比较单纯化疗(56例)与免疫联合化疗(47例)。两组不良事件、R0切除率、住院费用及术后总体并发症发生率均无显著差异;免疫联合化疗组肿瘤退缩分级0和1级比例显著更高(36.2%比14.3%,P=0.010)。
要点
- 新辅助免疫联合化疗不增加进展期胃癌患者不良事件及术后并发症风险。
- 免疫联合化疗组肿瘤退缩分级0和1级比例显著高于单纯化疗组。
- 两组R0切除率、住院费用及术后总体并发症发生率无显著差异。
核心结论
- 新辅助免疫联合化疗治疗进展期胃癌的不良事件发生率、手术切除难度及术后并发症发生率与单纯化疗相当。
- 免疫治疗的加入在肿瘤退缩分级短期疗效方面可能较单纯化疗有更好表现。
研究设计与样本
- 本研究为回顾性队列研究,收集2021年1月至2024年12月在华中科技大学同济医学院附属同济医院胃肠外科接受新辅助治疗并手术的103例进展期胃癌患者临床和病理资料。
- 患者分为单纯化疗组(56例)和免疫治疗联合化疗组(47例);男性70例,女性33例;年龄(58±10)岁(范围:29~79岁)。
- 两组年龄、性别分布、肿瘤部位及腹部手术史的差异均无统计学意义(P值均>0.05)。
- 组间数据比较采用Welch's t检验、χ2检验或Fisher确切概率法。
主要发现
- 新辅助治疗期间两组不良事件发生率差异无统计学意义[44.7%(21/47)比60.7%(34/56),χ2=2.640,P>0.05]。
- 两组R0切除率[97.9%(46/47)比91.1%(51/56)]和住院费用[(91 759±24 572)元比(96 873±17 367)元]差异均无统计学意义(P值均>0.05)。
- 两组术后总体并发症发生率差异无统计学意义[29.8%(14/47)比26.8%(15/56),χ2=0.114,P>0.05]。
- 免疫联合化疗组肿瘤退缩分级0级和1级比例较单纯化疗组高[36.2%(17/47)比14.3%(8/56)],差异有统计学意义(χ2=6.658,P=0.010)。
临床怎么用
- 对于进展期胃癌患者,新辅助免疫联合化疗可作为不增加术后并发症风险的治疗选择。
- 免疫联合化疗可能提高肿瘤退缩分级0和1级的比例,短期疗效优于单纯化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of neoadjuvant immunotherapy on intra-treatment complications, postoperative complications,and short-term efficacy in patients with advanced gastric cancer. Methods: This is a retrospective cohort study. Clinical and pathological data were collected from 103 patients with advanced gastric cancer who underwent neoadjuvant therapy and subsequent surgical treatment at the Department of Gastrointestinal Surgery, Affiliated Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,between January 2021 and December 2024. Among the patients,70 were male and 33 were female;the age was (58±10)years(range: 29 to 79 years). Patients were divided into two groups based on the neoadjuvant treatment regimen: the chemotherapy-alone group (56 patients) and the immunotherapy plus chemotherapy group(47 patients). There was no statistical significance in the differences of age, gender distribution, tumor location and abdominal surgery history between the two groups (all P>0.05). Comparisons between the two groups were performed using Welch's t-test,χ2 test or Fisher's exact probability test,respectively. Results: No statistically significant differences were observed in the incidence of adverse events during neoadjuvant therapy between the two groups (44.7%(21/47) vs. 60.7% (34/56),P>0.05). There were also no statistically significant differences in R0 resection rates (97.9%(46/47) vs. 91.1%(51/56)) and hospitalization costs for surgery((91 759±24 572) yuan vs. (96 873±17 367) yuan) between the two groups (both P>0.05). Additionally,the overall postoperative complication rates between the two groups were not significantly different (29.8%(14/47) vs. 26.8%(15/56) ,χ2=0.114,P>0.05).In terms of short-term efficacy,the proportion of responders(tumor regression grade 0 and 1) was significantly higher in the immunotherapy plus chemotherapy group compared to the chemotherapy-alone group (36.2%(17/47) vs. 14.3%(8/56), χ2=6.658, P=0.010). Conclusions: Neoadjuvant immunotherapy combined with chemotherapy does not increase the incidence of adverse events,surgical resection difficulty,or postoperative complications compared to chemotherapy alone. In terms of short-term efficacy,the addition of immunotherapy shows better performance in tumor regression grade compared to chemotherapy alone. 目的: 探讨新辅助免疫治疗对进展期胃癌患者治疗期间及术后并发症、短期疗效的影响。 方法: 本研究为回顾性队列研究。收集2021年1月至2024年12月在华中科技大学同济医学院附属同济医院胃肠外科接受新辅助治疗并进行手术治疗的103例进展期胃癌患者的临床和病理学资料。男性70例,女性33例;年龄(58±10)岁(范围:29~79岁)。按照新辅助治疗方案不同,将患者分为单纯化疗组(56例)和免疫治疗联合化疗组(47例)。两组年龄、性别分布、肿瘤部位及腹部手术史的差异均无统计学意义(P值均>0.05)。组间数据的比较采用Welch′s t检验、χ2检验或Fisher确切概率法。 结果: 新辅助治疗期间两组不良事件发生率的差异无统计学意义[44.7%(21/47)比60.7%(34/56),χ2=2.640,P>0.05]。两组患者的R0切除率[97.9%(46/47)比91.1%(51/56)]、住院费用[(91 759±24 572)元比(96 873±17 367)元]的差异均无统计学意义(P值均>0.05);两者术后总体并发症发生率的差异亦无统计学意义[29.8%(14/47)比26.8%(15/56),χ2=0.114,P>0.05]。在短期疗效方面,免疫联合化疗组肿瘤退缩分级0级和1级的比例较单纯化疗组高[36.2%(17/47)比14.3%(8/56)],差异有统计学意义(χ2=6.658,P=0.010)。 结论: 新辅助免疫治疗联合化疗治疗进展期胃癌患者的不良事件发生率、手术切除难度及术后并发症发生率与单纯化疗相当。在短期疗效方面,免疫治疗的加入可能较单纯化疗有更好的表现。.
引用
- Shi AN, Zhou YB, Wang GH, et al. [The impact of neoadjuvant immunotherapy on postoperative complications and short-term efficacy in patients with advanced gastric cancer]. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40443333. doi:10.3760/cma.j.cn112139-20250310-00121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。